Zynex (ZYXI) Lowered to “Hold” at Zacks Investment Research

Zynex (OTCMKTS:ZYXI) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Saturday. They currently have a $3.50 target price on the stock. Zacks Investment Research‘s price objective would suggest a potential upside of 12.90% from the company’s previous close.

According to Zacks, “Zynex, Inc. engineers, manufactures, markets, and sells medical devices for the electrotherapy, and stroke and spinal cord injury rehabilitation markets primarily in the United States. The company primarily offers electrotherapy products for pain relief and pain management; and NeuroMove for stroke and spinal cord injury rehabilitation. The company’s product lines are fully developed, FDA-cleared, commercially sold, and have been developed to uphold the Company’s mission of improving the quality of life for patients suffering from impaired mobility due to stroke, spinal cord injury, or debilitating and chronic pain. Zynex markets its products through commissioned and independent sales representatives, as well as directly to end users through advertisements and articles in relevant publications and on the Internet. The company is headquartered in Littleton, Colorado. “

ZYXI has been the subject of a number of other reports. ValuEngine downgraded Zynex from a “hold” rating to a “sell” rating in a research note on Friday, August 3rd. B. Riley began coverage on Zynex in a research note on Wednesday, October 10th. They set a “buy” rating and a $7.00 price objective for the company.

Shares of OTCMKTS ZYXI traded down $0.05 during trading on Friday, reaching $3.10. The stock had a trading volume of 6,351 shares, compared to its average volume of 15,622. Zynex has a one year low of $1.10 and a one year high of $5.50. The company has a market capitalization of $104.17 million, a price-to-earnings ratio of 14.09 and a beta of 0.95.

Zynex (OTCMKTS:ZYXI) last issued its quarterly earnings results on Tuesday, November 6th. The company reported $0.08 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.07 by $0.01. Zynex had a return on equity of 152.81% and a net margin of 33.33%. The business had revenue of $8.13 million during the quarter, compared to the consensus estimate of $7.96 million. Research analysts forecast that Zynex will post 0.28 EPS for the current year.

Zynex Company Profile

Zynex, Inc, a medical technology company, designs, manufactures, and markets electrotherapy medical devices used for pain management and rehabilitation. Its products include NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation device; NeuroMove, an electromyography triggered electrical stimulation device; and InWave, an electrical stimulation product for the treatment of female urinary incontinence.

See Also: Why investors pay attention to retained earnings

Get a free copy of the Zacks research report on Zynex (ZYXI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Zynex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zynex and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply